MLYS (Mineralys Therapeutics) Buyback Yield %: -17.21 (As of Jul. 01, 2026)


MLYS Mineralys Therapeutics Inc MLYS
35 GF Score
Price $26.89
! 2 Warning Signs
View Full Analysis

What is Mineralys Therapeutics Buyback Yield %?

Mineralys Therapeutics MLYS -0.33% 35 Buyback Yield % is -17.21 as of Jul. 01, 2026. GuruFocus rates MLYS with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 745 Biotechnology companies, Mineralys Therapeutics ranks worse than 63.49% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Mineralys Therapeutics's current buyback yield was -17.21%.

Mineralys Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Mineralys Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mineralys Therapeutics Buyback Yield % Chart

Mineralys Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial 0.00 0.00 -57.38 -18.92 -19.55

Mineralys Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.36 -22.25 -16.24 -19.55 -18.33

MLYS vs VCEL, NRIX, PHVS: Buyback Yield % Comparison

For the Biotechnology subindustry, Mineralys Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mineralys Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Mineralys Therapeutics's Buyback Yield % falls into.


MLYS
35GF Score
Mineralys Therapeutics Inc MLYS
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mineralys Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Mineralys Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 578.361) / 2958.97773
=-19.55%

Mineralys Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 409.413) / 2233.70595
=-18.33%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -17.21 mean?
Mineralys Therapeutics (MLYS) has a Buyback Yield % of -17.21 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mineralys Therapeutics and its competitors. According to the industry distribution chart, Mineralys Therapeutics ranks #473 out of 745 companies in the Biotechnology industry, placing it in the top 63.5%.
Is Mineralys Therapeutics' Buyback Yield % too high?
Mineralys Therapeutics' current Buyback Yield % is -17.21. Based on the distribution chart, Mineralys Therapeutics ranks #473 out of 745 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mineralys Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Buyback Yield % compare to VCEL and NRIX?
According to the Biotechnology industry distribution chart, Mineralys Therapeutics ranks #473 out of 745 companies for Buyback Yield %. This places Mineralys Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mineralys Therapeutics and its competitors. Mineralys Therapeutics's current Buyback Yield % is -17.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Buyback Yield % of -17.21. The current Buyback Yield % is -17.21. Mineralys Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Buyback Yield % is -17.21 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mineralys Therapeutics Business Description

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
35GF Score

Get the complete analysis for MLYS

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.89
Price